Detalhe da pesquisa
1.
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Support Care Cancer
; 32(1): 36, 2023 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38105286
2.
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.
Support Care Cancer
; 31(12): 628, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37828258
3.
Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy.
Molecules
; 25(7)2020 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244751
4.
Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
BMC Cancer
; 18(1): 917, 2018 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249215
5.
Transforming growth factor-ß1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma.
Transl Oncol
; 42: 101867, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308919
6.
Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
Front Oncol
; 13: 1097309, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37064132
7.
Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response.
Cancers (Basel)
; 14(10)2022 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35626126
8.
Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.
Front Immunol
; 13: 823842, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35677046
9.
Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma.
Transl Oncol
; 19: 101384, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35255355
10.
The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy.
Ann Palliat Med
; 10(3): 2679-2686, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549001
11.
High Mobility Group Box 1 in Human Cancer.
Cells
; 9(7)2020 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32664328
12.
Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer.
Lung Cancer Manag
; 9(3): LMT37, 2020 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32774468
13.
Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review.
Front Oncol
; 9: 659, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31396484
14.
Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.
Expert Opin Drug Saf
; 16(6): 697-710, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28460548
15.
Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Expert Rev Clin Pharmacol
; 10(1): 17-29, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27894202
16.
Analysis of primary endocrine therapy in patients older than 70 years with breast cancer rejecting surgery from a single unit in South Africa including COVID-19 issues.
J Geriatr Oncol
; 12(7): 1118-1121, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33707048